← All trials
NCT05462704
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2022
- Primary completion
- Jul 31, 2026
- Completion date
- Apr 30, 2027
- First posted
- Jul 18, 2022
- Last posted
- Jul 18, 2022
- Enrollment
- 746
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Brown UniversityLead sponsor
- University of MichiganCollaborator
- Washington University in St. LouisCollaborator
- Brown UniversityOverall official - principal investigator
- Brown UniversityReponsible party - principal investigator
- Brown UniversityOfficial
- Brown UniversitySponsor investigator
- Oregon Health and Science UniversityCollaborator
- University of Alabama, BirminghamCollaborator
- University of UtahCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.